Description  Claims  Drawing  Cited references 

WO2008057158A2   [0016] 
WO8705330A   [0079] 
US5589466A   [0087] 
WO9208495A   [0092] 
WO9114438A   [0092] 
WO8912624A   [0092] 
US5314995A   [0092] 
EP396387A   [0092] 
US6514496B   [0097] 
US3773919A   [0101] 
WO61793788A   [0171] 

J Acquir Immune Defic Syndr   [0008] 
Immunol Today   [0008] 
Virology   [0009] 
J Virol   [0009] 
J Virol   [0009] 
Immunology   [0017] 
Vaccine   [0018] 
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14   [0043] 
Evidence for at least two dominant neutralization antigens on human rhinovirus 14   [0043] 
J Immunol.   [0056] 
Science   [0062] 
Proc Nat. Acad Sci USA   [0062] 
Proteins, Structures and Molecular Principles   [0068] 
Introduction to Protein Structure   [0068] 
Nature   [0068] 
Proteins: Structure and Molecular Properties   [0078] 
Crit Rev Biochem   [0079] 
Arch Biochem Biophys   [0080] 
Anal Biochem   [0080] 
Meth Enzymol   [0080] 
A Guide to Methods and Applications, Academic   [0081] 
Proc Natl Acad Sci   [0081] 
Vaccine   [0087] 
J. Immunol.   [0087] 
Inf. Immunol.   [0087] 
Vaccine   [0087] 
J. Virol   [0087] 
J. Biol. Chem.   [0087] 
J. Immunol.   [0087] 
J. Chemother.   [0087] 
J. Human Virol.   [0087] 
New Generation Vaccines   [0089] 
Science   [0095]  [0099] 
Liposomes in the Therapy of Infectious Disease and Cancer   [0095] 
Remington's Pharmaceutical Sciences   [0096]  [0102] 
CRC Crit Ref Biomed Eng   [0099] 
Surgery   [0099] 
N Engl J Med   [0099] 
Medical Applications of Controlled Release   [0099] 
Controlled Drug Bioavailability, Drug Product Design and Performance   [0099] 
J Macromol Sci Rev Macromol Chem   [0099] 
Science   [0099] 
Ann Neurol   [0099] 
J Neurosurg   [0099] 
Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination   [0170] 
Human rhinovirus type 16: mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis   [0170] 
Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates   [0170] 
Current estimates from the National Health Interview Survey   [0170] 
Neutralization epitopes of human rhinovirus type 2   [0170] 
Cost burden of viral respiratory infections: issues for formulary decision makers   [0170] 
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope   [0170] 
Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2   [0170] 
Structure of a neutralizing antibody bound bivalently to human rhinovirus 2   [0170] 
Structure of a neutralizing antibody bound monovalently to human rhinovirus 2   [0170] 
Human rhinoviruses: the cold wars resume   [0170] 
Emerging Infectious Diseases   [0170] 
Sequencing and Analyses of All Known Human Rhinovirus Genomes Reveals Structure and Evolution   [0170] 
The treatment of rhinovirus infections: progress and potentia   [0170] 
Structure of human rhinovirus serotype 2 (HRV2)   [0170] 
The nature and spatial distribution of amino acid substitutions conferring resistance to neutralizing monoclonal antibodies in human rhinovirus type 2   [0170]